Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy

Bibliography

• KANNEL WB: Hypertension as a risk factor for cardiac events-epidemiologic results of long-term studies..I.Cardiovasc.Pharmacol. (1993) 21\(Suppl. 2):S27–S37.
   Google Scholar
• OPARIL S, OBERMAN A: Nontraditional cardiovascular risk factors. Am. .1. Med. Sci.(1999) 317:193–207.
   PubMedGoogle Scholar
• AZEN SP, MACK WI,CASHIN-HEMPHILL L et al: Progressionof coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation (1996) 93:34–41.
   Google Scholar
• JUKEMA JW, BRUSCHKE AV, VAN BOVEN Al et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study(REGRESS). Circulation (1995) 91:2528–2540.
   Google Scholar
• SCHROEDER AP, FALK E: Vulnerable and dangerous coronary plaques. Atherosclerosis(1995) 118(Suppi.):S141–S149.
   Google Scholar
• TAKANO M, MIZUNO K,YOKOYAMA S et al.: Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J. Am. Coll Cardiol (2003) 42:680–686.
   Google Scholar
• EGASHIRA K, HIROOKA Y, KAI H et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.Circulation (1994) 89:2519–2524.
   PubMed Web of Science ®Google Scholar
• LACOSTE L, LAM JY, HUNG J et al: Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.Circulation (1995) 92:3172–3177.
   Google Scholar
• SHISHEHBOR MH, BRENNAN ML, AVILES RI et al.: Statins promote potent systemic antioxidant effects through specificinflammatory pathways. Circulation (2003) 108:426–431.
   PubMed Web of Science ®Google Scholar
• MAK IT, ZHANG J, WEGLICKI WB: Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide. Pharmacol Res. (2002) 45:27–33.
   PubMed Web of Science ®Google Scholar
• MASON RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis (2002) 165:191–199.
   PubMed Web of Science ®Google Scholar
• LAI YM, FUKUDA N, SU JZ et al.: Novelmechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats.Hypertens. Res. (2002) 25:109–115.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ R, CARVAJAL AR, ARMAS-DE HERNANDEZ MJ et al:Effects of amlodipine on platelet aggregation and blood pressure in patients\with essential hypertension. Clin.Ther:(1993) 15:304–313.
   PubMedGoogle Scholar
• MEYER G, MERVAL R, TEDGUI A: Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circ.Res. (1996) 79:532–540.
   PubMed Web of Science ®Google Scholar
• HEINECKE JW, BAKER L, ROSEN H, CHAIT A: Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. I Clin. Invest. (1986) 77:757–761.
   PubMed Web of Science ®Google Scholar
• ANDERSON TJ: Assessment and treatment of endothelial dysfunction in humans. I Am. Coll. Cardiol. (1999) 34:631–638.
   PubMed Web of Science ®Google Scholar
• CAI H, HARRISON DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. (2000) 87:840–844.
   PubMed Web of Science ®Google Scholar
• GIBBONS GH: Endothelial function as a determinant of vascular function and structure: a new therapeutic target. Am. Cardiol. (1997) 79:3–8.
   PubMedGoogle Scholar
• HEITZER T, SCHLINZIG T, KROHN K, MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104:2673–2678.
   PubMed Web of Science ®Google Scholar
• SCHIFFRIN EL: Beyond blood pressure: the endothelium and atherosclerosis progression. Am. Hypertens. (2002) 15:115S–122S.
   Google Scholar
• LERMAN A, BURNETT JC Jr: Intact andaltered endothelium in regulation of vasomotion. Circulation (1992) 86:11112–11119.
   Google Scholar
• SCHACHTER M: Calcium antagonists and atherosclerosis. Int.J.Cardiol. (1997) 62 (Suppl. 2):59–515.
   Google Scholar
• HENRY PD, BENTLEY KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. j Clin. Invest. (1981) 68:1366–1369.
   PubMed Web of Science ®Google Scholar
• JUKEMA JW, VAN BOVEN AJ, ZWINDERMAN AH, VAN DER LA, BRUSCHKE AV: Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovasc. Drugs Ther. (1998) 12\(Suppl. 1):111–118.
   Google Scholar
• UCHIDA H, TANAKA Y, ISHII K, NAKAYAMA K: L-type Ca2+ channels are not involved in coronary endothelial Ca2+ influx mechanism responsible for endothelium-dependent relaxation.aRes. Commun. Mol. Pathol. Pharmacol.(1999) 104:127-144.
   Google Scholar
• ZHANG X, HINTZE TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation (1998) 97:576–580.
   PubMed Web of Science ®Google Scholar
• PHILLIPS JE, PRESTON MR: Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: role of electrostatic interactions.Atherosclerosis (2003) 168:239–244.
   PubMedGoogle Scholar
• ROTH M, EICKELBERG 0, KOHLER E, ERNE P, BLOCK LH: Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc. Nati Acad. Sci. USA (1996) 93:5478–5482.
   PubMed Web of Science ®Google Scholar
• IKEDA U, HOJO Y, UENO S, ARAKAWA H, SHIMADA K: Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. Cardiovasc. Pharmacol. (2000) 35:887–890.
   PubMedGoogle Scholar
• SIMA A, STANCU C,CONSTANTINESCU E, OLOGEANU L, SIMIONESCU M: The hyperlipemic hamster - a model for testing the anti-atherogenic effect of amlodipine. Cell Mol. Med. (2001) 5:153–162.
   PubMedGoogle Scholar
• TURGAN N, HABIF S, KABAROGLU CG et al.: Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid perwddation, antioxidant status and aortic histology in cholesterol-fed rabbits.Biomed. Sci (2003) 10:65–72.
   Google Scholar
• HOSHIDA S, YAMASHITA N, KUZUYA T, HORT M: Reduction in infarct size by chronic amlodipine treatment in cholesterol-fed rabbits. Atherosclerosis (1998) 138:163–170.
   PubMedGoogle Scholar
• LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W et al.: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.Lancet (1990) 335:1109–1113.
   Google Scholar
• PITT B, BYINGTON RP, FURBERG CD et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 102:1503–1510.
   PubMed Web of Science ®Google Scholar
• ZANCHETTI A, BOND MG, HENNIG M et al.: Calcium antagonistalacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106:2422–2427.
   PubMed Web of Science ®Google Scholar
• DENS JA, DESMET WJ,COUSSEMENT P et al.: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart (2003) 89:887–892.
   Google Scholar
• GHIADONI L, MAGAGNA A, VERSARI D et al.: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension (2003) 41:1281–1286.
   PubMed Web of Science ®Google Scholar
• FARNIER M, DAVIGNON J: Current andfuture treatment of hyperlipidemia: the role of statins. Am. J. Cardiol. (1998) 82:3J–10J.
   Google Scholar
• NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl. Med. (1996) 335:1001–1009.
   Google Scholar
• NO AUTHORS LISTED: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl. Med. (1998) 339:1349–1357.
   Google Scholar
• YAMAMOTO A, HOSHI K,ICHIHARA K: Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid perwddation in rat liver microsomes. Eur. Pharmacol. (1998) 361:143–149.
   PubMedGoogle Scholar
• DELSING DJ, JUKEMA JW, VAN DE WIEL MA et al.: differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in APOE*3-leiden transgenic mice. I Cardiovasc. Pharmacol. (2003) 42:63–70.
   Google Scholar
• HERNANDEZ-PRESA MA,ORTEGO M, TUNON J et al.:Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than467lipid lowering diet. Cardievasc.Res. (2003) 57:168–177.
   Google Scholar
• KLEEMANN R, PRINCEN HM, EMEIS JJ et al.: Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation (2003) 108:1368–1374.
   PubMed Web of Science ®Google Scholar
• ORTEGO M, BUSTOS C, HERNANDEZ-PRESA MA et al.: Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis (1999) 147:253–261.
   PubMed Web of Science ®Google Scholar
• HERNANDEZ-PRESA MA,MARTIN-VENTURA IL, ORTEGO M et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.Atherosclerosis (2002) 160:49–58.
   Google Scholar
• DICHTL W, DULAK J, FRICK M et al.:HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biel (2003) 23:58–63.
   PubMed Web of Science ®Google Scholar
• ZHAO S, ZHANG DQ: Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits.aClin. Chim. Acta (2003) 336:103–108.
   PubMedGoogle Scholar
• HALOUI M, MEILHAC 0,JANDROT-PERRUS M, MICHEL JB: Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur. Pharmacel (2003) 474:175–184.
   PubMedGoogle Scholar
• NAWAWI H, OSMAN NS, ANNUAR R, KHALID BA, YUSOFF K: Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin. Atherosclerosis (2003) 169:283–291.
   PubMed Web of Science ®Google Scholar
• MCCORMICK LS, BLACK DM, WATERS D, BROWN WV, PITT B: Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT). Am. J. Cardiel (1997) 80:1130–1133.
   PubMed Web of Science ®Google Scholar
• JUKEMA JVV, ZWINDERMAN AH, VAN BOVEN AJ et al.: Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscier. DIFOR1/1. V3SC. Biol. (1996) 16:425–430.
   Google Scholar
• NO AUTHORS LISTED: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation (2003) 107:422–428.
   PubMedGoogle Scholar
• VAN DE POLL SW, DELSING DJ, WOUTER JJ et al.: Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice. j. Mel Cell Cardiel (2003) 35:109–118.
   Google Scholar
• MASON RP, JACOB RE KAY RD: Synergistic stimulation of nitric oxide release from human endothelial cells with amlodipine and atorvastatin. Eur. Heart J. (2003) 24(Suppl.):214 (Abstract).
   Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361:1149–1158.
   PubMed Web of Science ®Google Scholar
• LEIBOVITZ E, BENIASHVILI M, ZIMLICHMAN R et al.: Treatment with amlodipine andatorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am. Hypertens. (2003) 16:715–718.
   PubMed Web of Science ®Google Scholar
• SEVER PS, DAHLOF B, POULTER NR et al.: Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J. Hypertens. (2001) 19:1139–1147.
   PubMed Web of Science ®Google Scholar